AI English summary of an SEC filing — figures as filed
Regeneron Pharmaceuticals REGNThe company said its total revenues for Q4 2025 were $3,884 million, up 3% from a year earlier, and its full-year total revenues were $14,343 million, up 1%. GAAP net income for Q4 was $845 million, down 8%, and full-year GAAP net income was $4,505 million, up 2%.
Key points
AI summaryThe company said its total revenues for Q4 2025 were $3,884 million, up 3% from a year earlier, and its full-year total revenues were $14,343 million, up 1%. GAAP net income for Q4 was $845 million, down 8%, and full-year GAAP net income was $4,505 million, up 2%.
The company said U.S. net sales of EYLEA HD for Q4 2025 rose 66% to $506 million, while combined U.S. net sales of EYLEA HD and EYLEA fell 28% to $1.1 billion. Combined U.S. net sales of EYLEA HD and EYLEA for the full year fell 27% to $4.4 billion.
Sanofi collaboration revenue for Q4 2025 rose 35% to $1,640 million, Regeneron said. It cited an increase in the company's share of profits from antibody commercialization, which was $1.486 billion in Q4 compared with $1.043 billion a year earlier, as the driver. Global net sales of Dupixent, as recorded by Sanofi, were $4.9 billion in Q4.
Regeneron said it recorded the cost of shares repurchased in Q4 2025 at $671 million and for the full year at $3.5 billion as treasury stock. As of December 31, 2025, $1.5 billion remained available for share repurchases under its programs. The company also gave its 2026 GAAP R&D outlook as $6.450 to $6.680 billion.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Q4 2025 Revenue and Full-Year GAAP Net Income
The company said its total revenues for Q4 2025 were $3,884 million, up 3% from a year earlier, and its full-year total revenues were $14,343 million, up 1%. GAAP net income for Q4 was $845 million, down 8%, and full-year GAAP net income was $4,505 million, up 2%.
Source · Based on the filing body and exhibits
U.S. Net Sales of EYLEA HD and EYLEA
The company said U.S. net sales of EYLEA HD for Q4 2025 rose 66% to $506 million, while combined U.S. net sales of EYLEA HD and EYLEA fell 28% to $1.1 billion. Combined U.S. net sales of EYLEA HD and EYLEA for the full year fell 27% to $4.4 billion.
Source · Based on the filing body and exhibits
Higher Sanofi Collaboration Revenue and Dupixent Net Sales
Sanofi collaboration revenue for Q4 2025 rose 35% to $1,640 million, Regeneron said. It cited an increase in the company's share of profits from antibody commercialization, which was $1.486 billion in Q4 compared with $1.043 billion a year earlier, as the driver. Global net sales of Dupixent, as recorded by Sanofi, were $4.9 billion in Q4.
Source · Based on the filing body and exhibits
Shareholder Returns and 2026 R&D Outlook
Regeneron said it recorded the cost of shares repurchased in Q4 2025 at $671 million and for the full year at $3.5 billion as treasury stock. As of December 31, 2025, $1.5 billion remained available for share repurchases under its programs. The company also gave its 2026 GAAP R&D outlook as $6.450 to $6.680 billion.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…